Thu, Jul 24, 2014, 8:09 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

  • koleminer1 koleminer1 Dec 30, 2013 12:59 AM Flag

    Rami Daoud is Stuart Sedlack's Replacement

    What do we know about Rami and what could it mean for Amarin?

    Anybody find anything on a new Chief Commercial Officer yet (replace Paul Huff)?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From Linkedin:

      Summary
      Seasoned pharmaceutical professional with an extensive business development, strategy and financial experiences. Proven deal maker with an excellent reputation, extensive global BD network, exceptional financial and analytical skills, strong scientific background, good business acumen and a determination to drive deals & projects to successful conclusions.

      Specialties:Sourcing product or company partnership opportunities. Managing multi-functional due diligence assessments. Conducting market research and estimating commercial potential. Robust financial modeling and analyses to value projects and terms. Developing appropriate positioning and communication strategy. Structuring and negotiating deals. Developing corporate, product or therapeutic area strategies. Assisting early stage companies in business plan preparation, BD projects and financing.

      Experience
      Vice President, Business DevelopmentAmarin Corporation
      June 2013 – Present (7 months)Executive Director, Business DevelopmentACEA Biosciences
      July 2012 – June 2013 (1 year)|Greater San Diego Area
      Head of business development for ACEA Biosciences' Pharmacutical and Technologies business units.

      President and FounderRD Consulting, LLC
      2011 – 2012 (1 year)|Greater Philadelphia Area
      Transaction advisory firm providing business development, strategic and financial consulting support for pharmaceutical, biotech and medical device companies.

      Senior Director, Business DevelopmentAuxilium Pharmaceuticals
      2004 – 2011 (7 years)Manager, Business DevelopmentTransform Pharmaceuticals
      2003 – 2004 (1 year)Senior Associate, Corporate Business DevelopmentEli Lilly and Company
      2001 – 2003 (2 years)Senior Research Associate, Pre-Clinical R&DHuman Genome Sciences
      1996 – 2000 (4 years)|Washington D.C. Metro Area
      BiologistNational Institutes of Health
      1993 – 1995 (2 years)|Washington D.C. Metro Area

 
AMRN
1.57-0.01(-0.63%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.